PYC Therapeutics Reports Governance Update and Clinical Trials

PYC Therapeutics Limited (AU:PYC) has released an update.

PYC Therapeutics Limited, a clinical-stage biotech firm, has announced the submission of its Corporate Governance Statement and Appendix 4G for the fiscal year ending June 30, 2024. The company, which specializes in RNA therapies for genetic diseases, is currently advancing clinical trials for two blinding diseases in children and anticipates initiating trials for Polycystic Kidney Disease in early 2025. PYC is committed to robust corporate governance, adhering to the ASX Corporate Governance Principles, and continuously reviews its policies as the company grows.

For further insights into AU:PYC stock, check out TipRanks’ Stock Analysis page.